WO2005085462A1 - Preparation enzymatique d'un aminoacide beta-2 enrichi de maniere enantiomere - Google Patents

Preparation enzymatique d'un aminoacide beta-2 enrichi de maniere enantiomere Download PDF

Info

Publication number
WO2005085462A1
WO2005085462A1 PCT/EP2005/002103 EP2005002103W WO2005085462A1 WO 2005085462 A1 WO2005085462 A1 WO 2005085462A1 EP 2005002103 W EP2005002103 W EP 2005002103W WO 2005085462 A1 WO2005085462 A1 WO 2005085462A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
amino acid
defined above
optionally substituted
process according
Prior art date
Application number
PCT/EP2005/002103
Other languages
English (en)
Inventor
Bernardus Kaptein
Quirinus Bernardus Broxterman
Joannes Gerardus Theodorus Kierkels
Thierry Milcent
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to EP05715607A priority Critical patent/EP1745137A1/fr
Publication of WO2005085462A1 publication Critical patent/WO2005085462A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C12P13/222—Phenylalanine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture

Definitions

  • the invention relates to an enzymatic process for the preparation of an enantiomerically enriched ⁇ 2 -amino acid (ester).
  • An enzymatic process for the preparation of an enantiomerically enriched ⁇ 2 -amino acid (ester) is unknown.
  • Rossi D. et al. (1977) vol. 33, no. 12, pp 1557-1559, P 009030088 Basel ISSN 0014-4754 it is disclosed that N-phenylacetyl derivates of amino acids can be hydrolysed to produce optically active ⁇ -amino acids.
  • EP-A-1 367 129 discloses a process for the preparation of enantiomerically enriched N-unprotected ⁇ -amino acids by enzymatic hydrolysis of a mixture of enantiomers of N-unprotected ⁇ -amino acid esters using a hydrolase, wherein the hydrolysis occurs in a two-phase system of water and an organic solvent that, under the given reaction conditions, forms a two-phase system with water.
  • 61, 6893-6900 discloses a slightly related enzymatic process to a different compound in which an enantiomerically enriched 3-amino-2-methyl-propionic acid is prepared by reacting racemic N-protected 3-amino-2-methyl-propionic acid methyl ester with immobilized
  • Candida Antarctica lipase relates to N-protected ⁇ 2 -amino acids and N-protected ⁇ 2 -amino acid esters. Furthermore, a disadvantage of this process is that it is necessary to use a multistep kinetic resolution in order to get an acceptable enantiomeric excess of 3-amino-2-methyl-propionic acid. It is the object of the invention to provide a simple enzymatic process for the preparation of an enantiomerically enriched ⁇ 2 -amino acid (ester), i.e. a process without the need of multistep kinetic resolutions and/or N-protection of the ⁇ 2 -amino acid (ester). This object is achieved according to the invention by reacting a stereoselective hydrolytic enzyme with a mixture of enantiomers of a ⁇ 2 -amino acid ester represented by formula 2
  • esters which process leads to ⁇ 2 -amino acid (ester)s with an acceptable enantiomeric excess. Furthermore, the process of the invention is well scalable and can be applied at an industrial scale. With ⁇ -amino acid (ester) is meant a ⁇ -amino acid(ester) substituted on the 2-position ( ⁇ -position). For a definition of ⁇ 2 -amino acid(ester) see also Sewald,
  • the ⁇ 2 -amino acid (ester) of formula 2 has a chiral center on at least the ⁇ -position; the ⁇ 2 -amino acid (ester) of formula 2 may however also have other chiral centers, for example the carbon atom to which R 2 , R 3 and R 4 are attached may be chiral; this carbon atom is chiral when R 2 , R 3 and R 4 are not the same.
  • 'mixture of enantiomers' is meant a random mixture of (R) and (S)-enantiomers.
  • R 1 stands for an optionally substituted alkyl of 1-20 C- atoms, more preferably of 1-12 C-atoms (C-atoms of the substituents included).
  • R 1 may stand for a C C alkyl, e.g. methyl, ethyl, n-butyl; substituted methyl, e.g.
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 each independently stand for H, an optionally substituted alkyl of 1-12 C-atoms, more preferably of 1-8 C-atoms (C-atoms of the substituents included) or for a (hetero)aryl of 5 2-10 C-atoms (C-atoms of the substituents included).
  • the heteroatom(s) is/are chosen from the group of N, O and S.
  • R 2 and R 3 , R 2 and R 4 or R 3 and R 4 may form a ring of preferably 3-6 C-atoms.
  • the ring they form may for example be a (hetero)cycloalkyl or a (hetero)aryl, each of which rings may optionally be substituted.
  • substituents include alkyl, (hetero)aryl, sulfonyl, alkoxycarbonyl, amidocarbonyl, nitrile, hydroxy, alkoxy, aryloxy, thioalkyl, mercapto, amino and fluorine.
  • Collecting includes for example isolation by means of conventional methods, for example ultrafiltration, concentration, column chromatography, extraction 0 or crystallization and further reaction of the obtained product (enantiomerically enriched ⁇ 2 -amino acid or enantiomerically enriched ⁇ 2 -amino acid ester).
  • Hydrolytic enzymes are also known as hydrolases. Hydrolases are enzymes that catalyze a hydrolysis reaction. Thus, hydrolases act to break down a compound (i.e. the substrate) by cleaving a covalent bond in the compound and 5 inserting a water molecule across the bond.
  • the hydrolytic enzyme has an E-ratio > 5, more preferably an E-ratio > 10, even more preferably an E-ratio > 50, most preferably an E-ratio > 100.
  • a stereoselective hydrolytic enzyme suitable for use in the present invention may for example be found in one of the general classes of hydrolytic enzymes, for instance in the group of esterases, lipases, proteases, peptidases or acylases, preferably in the group of esterases or lipases.
  • the stereoselective hydrolytic enzyme is found in the group of enzymes classified as carboxylic ester hydrolases (EC 3.1.1) or in the group of enzymes classified as peptidases, for example EC 3.4.1, EC 3.4.11, EC 3.4.21, more preferably EC 3.4.21.62, EC 3.4.22 or EC 3.4.23.
  • a stereoselective hydrolytic enzyme may also be found in the group of commercially available hydrolytic enzymes.
  • hydrolytic enzymes examples include enzymes supplied by Fluka: Candida cylindracea lipase, lipase Hog pancreas, lipase Pseudomonas fluorescens, lipase Aspergillus oryzae, lipase Rhizopus niveus, lipase Rhizomucor miehei, lipase Candida antarctica, lipase Mucor javanicus, lipase Rhizopus arrhizus, lipase Penicillium roqueforti, lipase Candida lipolytica, lipoprotein lipase Pseudomonas sp., type B, lipoprotein lipase Pseudomonas cepacia, lipoprotein lipase Chromobacterium viscosum, esterase Bacillus stearothermophilus, esterase Bacillus thermoglucosidasius, esterase Mucor miehei,
  • stereoselective hydrolytic enzymes are: subtilisin, alcalase 2.5L, Bacillus licheniformis protease, Candida Antarctica lipase A, porcine pancreatic lipase type II.
  • the stereoselective hydrolytic enzyme may be used in any form.
  • the hydrolytic enzyme may be used - for example in the form of a dispersion, a solution or in immobilized form - as crude enzyme, as a commercially available enzyme, as an enzyme further purified from a commercially available preparation, as an enzyme obtained from its source by a combination of known purification methods, in whole (optionally permeabilized and/or immobilized) cells that naturally or through genetic modification possess the required stereoselective hydrolytic enzyme activity, or in a lysate of cells with such activity. It will be clear to the average person skilled in the art that use can also be made of mutants of naturally occurring (wild type) enzymes with hydrolytic activity in the process according to the invention.
  • Mutants of wild-type enzymes can for example be made by modifying the DNA encoding the wild type enzymes using mutagenesis techniques known to the person skilled in the art (random mutagenesis, site-directed mutagenesis, directed evolution, gene shuffling, etc.) so that the DNA encodes an enzyme that differs by at least one amino acid from the wild type enzyme and by effecting the expression of the thus modified DNA in a suitable (host) cell.
  • Mutants of the stereoselective hydrolytic enzyme may have improved properties with respect to (stereo)selectivity and/or activity and/or stability and/or solvent resistance and/or pH prophile and/or temperature prophile.
  • a stereoselective hydrolytic enzyme may for example be selected for the process of the invention by screening several enzymes or host cells expressing genes encoding enzymes for the presence of stereoselective hydrolytic enzyme activity.
  • the person skilled in the art knows how to screen for enzymes with a desired activity.
  • conditions under which the substrate (such as the compound of formula 2) and the enzyme are brought into contact are chosen such that it is a good compromise between on the one hand the stability of the enzyme, the substrate and the reaction product and on the other hand the reaction velocity (which usually increases at higher temperatures). Screening for enzymes may be performed at any scale. For practical reasons, if large numbers of enzymes are screened, a reaction volume between 0.15ml and 10ml is used.
  • stereoselective hydrolytic enzymes suitable for the stereoselective hydrolysis of a compound of formula 2 by monitoring the progress of the hydrolysis of the compound of formula 2 in an aqueous solution in the presence of an enzyme using an analytical method, for example TLC, HPLC or GC.
  • aqueous solutions are water and water with co-solvent, for example a water-miscible organic solvent or a water-immiscible solvent.
  • water-miscible organic solvents include methanol, ethanol, aceton, dioxane, acetonitrile, tetrahydrofuran, dimethylsulfoxide and dimethylformamide.
  • water-immiscible organic solvents examples include methyl-t-butyl ether, methyl-isobutyl ketone.toluene, hexane, xylene and iso-octane.
  • the amount of co-solvent is in principle not critical and is usually chosen between 5 and 25 % v/v. In case the substrate is liquid it may be present in water as such. In case the substrate is solid, it may be advantageous that a co-solvent is also present.
  • the enzyme/substrate ratio in the 'hydrolysis screening' is in principle not critical and may be chosen between 1/20 and 2/1.
  • the amount of substrate used is in principle also not critical and may for example be between 5mM and 1.5 M.
  • the pH of the 'hydrolysis screening' is in principle not critical and may for example be chosen between 5 and 10, preferably between 6 and 8 and may be kept constant by using a buffered aqueous solution using a buffer concentration of for example between 10mM and 500mM. Alternatively, the pH of the screening reaction may be kept constant by using an automated pH-stat system.
  • the temperature of the 'hydrolysis screening' is in principle not critical and may be chosen between 20 and 40°C. Alternatively, if an enzyme is sought, which should operate at high temperature, the temperature may be chosen higher. The choice of the reaction conditions of the process of the invention depends on the choice of hydrolytic enzyme.
  • the temperature of the process is chosen between 0 and 90°C, in particular between 10 and 40°C; usually the pH of the process is chosen between 4 and 10 and as a solvent usually water, an aqueous solvent, for example water/_-butanol or water/dioxane, or a two-phase system of water and a water immiscible solvent, for example toluene, hexane, heptane, methyl .-butyl ether, methyl iso-butyl ketone is used.
  • a solvent usually water, an aqueous solvent, for example water/_-butanol or water/dioxane, or a two-phase system of water and a water immiscible solvent, for example toluene, hexane, heptane, methyl .-butyl ether, methyl iso-butyl ketone.
  • the resulting enantiomerically enriched ⁇ 2 -amino acid of formula 1 obtained in the process of the invention may be isolated by using a known method for the isolation of an acid from water or from an aqueous layer.
  • the remaining enantiomerically enriched ⁇ 2 -amino acid ester of formula 2 obtained in the process of the invention may also be isolated in a manner known per se, for example by extraction with an organic solvent, crystallization or (ion exchange) chromatography.
  • the collected remaining enantiomerically enriched ⁇ 2 - amino acid ester of formula 2 is further hydrolysed to form the corresponding enantiomerically enriched ⁇ 2 -amino acid.
  • esters may be hydrolysed by acid hydrolysis using an aqueous solution of a mineral acid solution, for example HCI or H 2 SO 4 , by saponification using an aqueous solution of sodium hydroxide, or by enzymatic hydrolysis.
  • a mixture of enantiomers of ⁇ 2 -amino acid esters of formula 2, wherein R 1 , R 2 , R 3 and R 4 are as defined above may be prepared using methods known in the art.
  • a ⁇ 2 -amino acid ester of formula 2 may be prepared by reduction of the corresponding nitrile of formula 3
  • R 1 , R 2 , R 3 and R 4 are as defined above with a suitable reducing agent and optionally in the presence of a suitable catalyst.
  • the nitrile of formula 3, wherein R 1 , R 2 and R 3 are as defined above and wherein R 4 stands for H may be prepared by reduction of the double bond of the corresponding nitrile of formula 4,
  • the mixture of enantiomers of ⁇ 2 - amino acid esters of formula 2, wherein R 1 , R 2 and R 3 are as defined above and R 4 stands for H may be prepared by a one-pot reduction (this is: without isolation of the intermediate nitrile of formula 3) of the corresponding nitrile of formula 4 with a suitable reducing agent and optionally in the presence of a suitable catalyst. In this reduction both the double bond and the nitrile group of the compound of formula 3 are reduced.
  • Suitable reducing agents (and catalyst combinations) are known to the person skilled in the art and include for.
  • R 1 , R 2 and R 3 are as defined above in a manner known per se by introducing R 4 via nucleophilic 1 ,4-addition using a suitable nucleophile.
  • the person skilled in the art knows which nucleophiles to use to introduce the desired R 4 .
  • nucleophiles examples include alkyl lithium, for example methyl lithium; Grignard reagents; alkoxides, for example a salt of benzylalcohol, for instance the potassium salt; thiols, for example thioacetic acid or benzylmercaptan, both of which may be in the form of a salt; nitrogen nucleophiles, for example amines, for example hydroxylamine; azides; or imides, for example potassium phtalimide or potassium bisformimide.
  • a nitrile of formula 4 wherein R 1 , R 2 and R 3 are as defined above may also be prepared by condensation of a ketone or aldehyde of formula 6
  • Suitable bases and dehydrating reagents are well known in the art. Suitable bases, include for example piperidine, triethylamine, OH " , diazabicycloundecene (DBU) and diazabicyclononene (DBN). An example of a dehydrating reagent is ammoniumacetate.
  • a mixture of enantiomers of ⁇ 2 -amino acid esters of formula 2, wherein R 1 , R 2 , R 3 and R 4 are as defined above may, for example, also be prepared by reacting NH 3 or an NH 3 -analogue with the 2-substituted acrylic acid ester of formula 5
  • NH 3 -analogue a compound which will give the free amine in the compound of formula 2 (optionally after removal of a protecting group).
  • examples of NH 3 -analogues include benzylamine, dibenzylamine, azide, hydroxylamine, potassium phtalimide and potassium bisformimide.
  • Enantiomerically enriched ⁇ 2 -amino acids and enantiomerically enriched ⁇ 2 -amino acid esters may be used as building blocks in the preparation of pharmaceuticals and agrochemicals.
  • ⁇ 2 -homo-threonine can be used in the preparation of the pharmaceutically active ingredient of ⁇ -lactam antibiotics (EP290385, EP742223, EP371875, EP774463, C Fuganti et al. Org. Bio-Org.Chem (1993), 2247-2249).
  • ⁇ 2 -amino acids may for example also be used in the preparation of the pharmaceutically active ingredient of platelet aggregation inhibitors (US 5,344,957, WO93/07867) or in the preparation of the pharmaceutically active ingredient of enkephalinase inhibitors (to replace morphine, treatment of diarrhea, hypertension, cardiac insufficiency and as analgesics; EP 634396).
  • ⁇ 2 -amino acids/esters may also be used to prepare pharmaceutically active ingredients useful as an antibiotic (WO02/41886) or as a medicine against constipation (Drugs Fut. (2000), 25(12), p1308).
  • the invention therefore, also relates to a process wherein the enantiomerically enriched ⁇ 2 -amino acid (ester) prepared according to the invention is further converted into a pharmaceutically active ingredient in a manner known per se.
  • the invention also relates to a process wherein the pharmaceutically active ingredient as obtained above is formulated into a pharmaceutical composition comprising the pharmaceutically active ingredient and an excipient.
  • stereoselective hydrolytic enzyme suitable for use in the present invention may also be used in the preparation of an enantiomerically enriched ⁇ 2 -amino acid ester of formula (2), wherein R 1 , R 2 , R 3 and R 4 are as defined above from an enantiomerically enriched ⁇ 2 -amino acid ester of formula (8)
  • R 12 stands for an optionally substituted alkyl, but is not the same as R 1 , and an alcohol R 1 OH, wherein R 1 is as defined above.
  • R 1' stands for an optionally substituted alkyl of 1-20 C- atoms, more preferably of 1-12 C-atoms (C-atoms of the substituents included).
  • R 1' may stand for a C r C 4 alkyl, e.g. methyl, ethyl, /.-butyl; substituted methyl, e.g. benzyl; or substituted ethyl, e.g. trichloroethyl, methoxy-ethyl ortrifluoroethyl.
  • the molar amount of alcohol R 1 OH relative to the amount of amino acid ester of formula 8 is >5, more preferably > 10.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé pour préparer un aminoacide ß2 enrichi de manière énantiomère comprenant la mise en réaction d'une enzyme hydrolytique stéréosélective et d'un mélange d'énantiomères d'un ester d'aminoacide ß2 ; et la collecte dudit aminoacide ß2 enrichi de manière énantiomère ainsi obtenu. L'invention concerne également un procédé pour préparer un ester d'aminoacide ß2 comprenant la mise en réaction d'une enzyme hydrolytique stéréosélective et d'un mélange d'énantiomères d'un ester d'aminoacide ß2 et la collecte de l'ester d'aminoacide ß2 enrichi de manière énantiomère restant.
PCT/EP2005/002103 2004-02-27 2005-02-24 Preparation enzymatique d'un aminoacide beta-2 enrichi de maniere enantiomere WO2005085462A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05715607A EP1745137A1 (fr) 2004-02-27 2005-02-24 Preparation enzymatique d'un aminoacide beta-2 enrichi de maniere enantiomere

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04075597 2004-02-27
EP04075597.7 2004-02-27

Publications (1)

Publication Number Publication Date
WO2005085462A1 true WO2005085462A1 (fr) 2005-09-15

Family

ID=34917173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002103 WO2005085462A1 (fr) 2004-02-27 2005-02-24 Preparation enzymatique d'un aminoacide beta-2 enrichi de maniere enantiomere

Country Status (3)

Country Link
EP (1) EP1745137A1 (fr)
CN (1) CN1926241A (fr)
WO (1) WO2005085462A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132276A1 (fr) 2014-03-07 2015-09-11 F. Hoffmann-La Roche Ag Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
EP2796562A4 (fr) * 2011-12-19 2015-11-25 Sumitomo Chemical Co Procédé de fabrication d'un acide -substitué- -aminé optiquement actif
US11337982B2 (en) 2016-09-13 2022-05-24 Hoffmann-La Roche, Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11771699B2 (en) 2015-03-16 2023-10-03 Hoffmann-La Roche Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11873302B2 (en) 2019-03-25 2024-01-16 Hoffmann-La Roche Inc. Solid forms of a compound of HBV core protein allosteric modifier
WO2024153752A1 (fr) 2023-01-20 2024-07-25 Ferring B.V. Synthèse stéréosélective d'intermédiaires et synthèse de quinagolides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106316871B (zh) * 2016-08-25 2018-04-03 苏州山青竹生物医药有限公司 一种手性β2‑氨基酸衍生物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367129A2 (fr) * 2002-05-08 2003-12-03 Degussa AG Procédé pour la préparation enzymatique de beta amino acides enrichis en énantionères

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367129A2 (fr) * 2002-05-08 2003-12-03 Degussa AG Procédé pour la préparation enzymatique de beta amino acides enrichis en énantionères

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU ET AL: "Recent advances in the stereoselective synthesis of beta-amino acids", TETRAHEDRON, vol. 58, 2002, pages 7991 - 8035, XP004383841 *
SOLYMÁR ET AL: "Candida antarctica lipase A - a powerful catalyst for the resolution of heteroaromatic beta-amino esters", TETRAHEDRON: ASYMMETRY, vol. 13, 2002, pages 2383 - 2388, XP004392007 *
SOLYMÁR ET AL: "Lipase-catalysed kinetic resolution in organic solvents: an approach to enantiopure alpha-methyl-beta-alanine esters", TETRAHEDRON: ASYMMETRY, vol. 13, 2002, pages 1923 - 1928, XP004385918 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796562A4 (fr) * 2011-12-19 2015-11-25 Sumitomo Chemical Co Procédé de fabrication d'un acide -substitué- -aminé optiquement actif
WO2015132276A1 (fr) 2014-03-07 2015-09-11 F. Hoffmann-La Roche Ag Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
US9233978B2 (en) 2014-03-07 2016-01-12 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US10081627B2 (en) 2014-03-07 2018-09-25 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US10428069B2 (en) 2014-03-07 2019-10-01 Hoffmann-La Roche Inc. 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
US11771699B2 (en) 2015-03-16 2023-10-03 Hoffmann-La Roche Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11337982B2 (en) 2016-09-13 2022-05-24 Hoffmann-La Roche, Inc. Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11873302B2 (en) 2019-03-25 2024-01-16 Hoffmann-La Roche Inc. Solid forms of a compound of HBV core protein allosteric modifier
WO2024153752A1 (fr) 2023-01-20 2024-07-25 Ferring B.V. Synthèse stéréosélective d'intermédiaires et synthèse de quinagolides

Also Published As

Publication number Publication date
CN1926241A (zh) 2007-03-07
EP1745137A1 (fr) 2007-01-24

Similar Documents

Publication Publication Date Title
WO2005085462A1 (fr) Preparation enzymatique d'un aminoacide beta-2 enrichi de maniere enantiomere
Patel Microbial/enzymatic synthesis of chiral drug intermediates
US9970043B2 (en) Process for producing optically active 2-alkyl-1,1,3-trialkoxycarbonylpropane
US5552317A (en) Method for preparing optically active homophenylalanine and esters thereof using lipase from wheat germ or Candida lipolytica
US5928933A (en) Process for the enzymatic resolution of N-(alkoxycarbonyl)-4-ketoproline alkyl esters or N-(alkoxycarbonyl)-4-hydroxyproline alkyl esters using Candida antarctica lipase B
EP0855446B1 (fr) Procédé de préparation de dérivés optiquement actifs de l'acide azetidine-2-carboxylique
JP3129663B2 (ja) 光学活性３−キヌクリジノール誘導体の製造法
US6440721B2 (en) Method for preparing an R- or S-form of α-substituted heterocyclic carboxylic acid and a counter enantiomeric form of α-substituted heterocyclic carboxylic acid ester thereto using enzyme
JP4765358B2 (ja) 光学活性なｎ−保護−プロパルギルグリシンの製造方法
US20050153401A1 (en) Process for preparing optically active beta-aminocarboxylic acids from racemic n-acylated beta-aminocarboxylic acids
US7449325B2 (en) Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof
JPH09206089A (ja) 光学活性アミノ酸誘導体の製法
EP2796562A1 (fr) Procédé de fabrication d'un acide -substitué- -aminé optiquement actif
US20040121435A1 (en) Biocatalytic preparation of enantiomerically enriched aminopentanenitrile
US6524844B2 (en) Process for preparing optically active 1-amino-4-(hydroxymethyl) cyclopent-2-ene derivatives
JP2003299495A (ja) 光学活性３−メチルグルタル酸モノエステルの製造方法
EP0259465A1 (fr) Procede de preparation de derives de l'acide 3-acylthio-2-methylpropionic optiquement actifs
JP2007117034A (ja) 光学活性ニペコチン酸化合物の製造方法
US5834261A (en) Method for the production of chiral vicinal aminoalcohols
Furutani et al. Resolution of N-acetyl-DL-methionine methyl ester by protease-catalyzed hydrolysis with mild base as the pH control reagent
WO2006006851A2 (fr) Procede destine a preparer un ester enrichi eniantomeriquement ou son acide correspondant
WO2006117057A1 (fr) Procede de fabrication d'acides e-(2s)- et (2r)-alkyl-5-halopento-4-ene-carboxyliques enrichis de façon enantiomerique ou de leurs esters
JP2006050990A (ja) 光学活性２−置換−３−（４−置換オキシフェニル）プロピオン酸およびその対掌体エステルの製造方法
JP2006006134A (ja) 光学活性なｎ−置換ピロリジン−３−カルボン酸の製造方法
US20030109029A1 (en) Process for the preparation of enantiomerically pure tertiary ss-hydroxycarboxylic acids or their esters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005715607

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580006312.2

Country of ref document: CN

Ref document number: 2007500183

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005715607

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005715607

Country of ref document: EP